EMMA · XBRL financial data

Emmaus Life Sciences financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (EMMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	5,018	7,067*	2,506	5,377	5,478	3,292*	2,406	2,817	3,378	3,852*	1,982	6,318
Cost of revenue	214	191*	257	241	394	309*	225	150	247	235*	168	344
Gross profit	4,804	6,876*	2,249	5,136	5,084	2,983*	2,181	2,667	3,131	3,617*	1,814	5,974
Research and development	414	166*	183	191	146	137*	176	56	50	31*	40	116
General and administrative	2,869	3,065*	2,869	2,732	2,799	2,287*	2,339	2,307	1,731	1,802*	1,850	1,574
Total operating expenses	4,780	5,521*	4,989	4,554	4,263	3,540*	3,161	3,037	2,436	2,731*	2,637	2,183
Operating income (loss)	24	1,355*	(2,740)	582	821	(557)*	(980)	(370)	695	886*	(823)	3,791
Interest expense	1,909	2,179*	1,910	966	1,338	1,278*	1,256	1,678	1,931	2,269*	2,126	1,596
Income tax expense (benefit)	38	(112)*	(7)	31	(1)	6*	4	(590)	579	16*	4	(1)
Net income (loss)	67	1,209*	(4,348)	(2,184)	1,827	(1,748)*	(2,330)	(1,135)	(2,076)	(1,951)*	(3,335)	1,339
Earnings per share, basic USD per share	0.00	0.02*	(0.07)	(0.03)	0.03	(0.03)*	(0.04)	(0.02)	(0.03)	(0.03)*	(0.05)	0.02
Earnings per share, diluted USD per share	(0.01)	—	(0.07)	(0.03)	(0.01)	—	(0.04)	(0.02)	(0.03)	(0.03)*	(0.05)	0.02
Weighted average shares, basic thousands of shares	53,638	55,154*	61,846	63,355	63,866	63,859*	63,866	63,866	63,866	64,553*	70,188	70,188
Weighted average shares, diluted thousands of shares	138,375	—	61,846	63,355	162,727	—	63,866	63,866	63,866	64,553*	70,188	120,537

Balance sheet

CSV

Fiscal quarters (EMMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,505	2,547	1,712	1,525	1,255	1,389	1,333	886	293	2,127	1,072	2,808
Accounts receivable	4,587	5,524	2,990	4,598	4,938	2,623	2,061	2,071	2,619	2,804	2,048	709
Inventory	1,650	1,711	1,527	1,628	1,610	1,635	1,437	1,313	1,213	1,555	1,909	1,589
Prepaid and other current assets	1,515	1,727	1,615	1,261	1,347	1,120	822	745	661	1,260	966	897
Total current assets	9,257	11,509	7,844	9,012	9,204	6,767	5,653	5,015	4,786	7,746	5,995	6,003
Property and equipment, net	60	59	57	54	49	46	41	143	128	113	98	86
Right-of-use asset	2,510	2,337	2,082	1,903	1,719	1,530	1,331	830	799	766	736	808
Total assets	47,453	35,179	29,543	25,939	27,343	23,602	22,478	23,344	20,756	21,436	18,696	16,370
Accounts payable	4,805	5,887	6,565	7,214	6,489	5,175	4,807	4,562	5,362	5,979	5,810	4,348
Accrued liabilities	8,164	8,174	8,519	8,163	7,864	7,732	8,740	9,032	9,562	9,321	10,238	9,944
Total current liabilities	60,917	61,507	62,428	64,025	64,131	63,555	64,915	62,076	64,169	69,072	70,537	66,116
Lease liability, non-current	2,070	1,839	1,561	1,322	1,076	815	544	1,584	1,498	1,409	1,324	1,299
Total liabilities	83,783	82,935	83,187	82,953	81,124	80,081	81,079	79,045	80,244	85,044	86,556	82,546
Accumulated deficit	(257,320)	(256,122)	(260,470)	(262,654)	(260,827)	(262,575)	(264,905)	(266,040)	(268,116)	(270,067)	(273,402)	(272,063)
Total stockholders' equity	(36,330)	(47,756)	(53,644)	(57,014)	(53,781)	(56,479)	(58,601)	(55,701)	(59,488)	(63,608)	(67,860)	(66,176)
Total liabilities and equity	47,453	35,179	29,543	25,939	27,343	23,602	22,478	23,344	20,756	21,436	18,696	16,370
Common shares outstanding (cover page) thousands of shares	53,638	61,846	63,866	63,866	63,866	63,866	63,866	63,866	63,866	70,188	70,188	70,188

Cash flows

CSV

Fiscal quarters (EMMA's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	67	1,209*	(4,348)	(2,184)	1,827	(1,748)*	(2,330)	(1,135)	(2,076)	(1,951)*	(3,335)	1,339
Stock-based compensation	24*	23*	170	29*	28*	29*	10	(1)*	9*	7*	1	0*
Depreciation and amortization	8*	6*	6	6*	5*	5*	5	4*	15*	15*	15	14*
Net cash from operating activities	58*	1,036*	140	(2,917)*	148*	343*	279	(2,908)*	409*	2,209*	(344)	1,693*
Purchases of property and equipment	0*	6*	4	3*	(1)*	6*	—	—	0*	0*	—	—
Net cash from investing activities	(399)*	(6)*	(4)	2,505*	1*	(2)*	0	2,171*	0*	0*	0	1,578*
Net cash from financing activities	494*	(5)*	(955)	235*	(438)*	(195)*	(345)	284*	(1,002)*	(362)*	(702)	(1,535)*
Net change in cash	144*	1,042*	(835)	(187)*	(270)*	134*	(56)	(448)*	(592)*	1,834*	(1,055)	1,736*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Avenue Therapeutics	1,942	0	(475)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026
International Stem Cell	1,089	2,675	167*	8.0M	—	Q2 FY26 10-QJun 30, 2026
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Nutra Pharma	not reported	34	(251)*	7.2B	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Mosaic ImmunoEngineering	0	not reported	(0)*	7.2M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Evoke Pharma	11,576	4,284	(522)*	1.7M	22.2 quarters	Q3 FY25 10-QSep 30, 2025
China Foods Holdings	16	0	(94)*	20.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Hepion Pharmaceuticals	1,629	not reported	(1,394)*	90.2M	1.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.